Malaysia extends Insulins supply contract with Biocon Biologics arm, Duopharma Marketing for additional 6 months
Bengaluru: Biocon Biologics Limited has announced that the Government of Malaysia has agreed to extend the current contract period of 36 months under the existing insulin supply agreement with its subsidiary in Malaysia, Biocon Sdn. Bhd., and Duopharma Marketing Sdn. Bhd. (DMktg), for an additional six months effective from April 29, 2025 until October 28, 2025.
Biocon Biologics has been the partner of choice for the Ministry of Health for its insulins requirement and has been serving patients in Malaysia for nearly 10 years. The company manufactures a range of recombinant human insulin products at its state- of- the- art facility in Johor, Malaysia. These insulin products are distributed in Malaysia through its commercial partner DMktg.
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025. The amendment to the contract will be formalised through the execution of a formal supplementary agreement between the MoH, DMktg and Biocon subsequently.
Read also: Biocon Biologics commercial partner launches psoriatic arthritis injection in Japan
Biocon Biologics is a global player in biosimilars and insulin production and has achieved many “firsts” in the industry including the first to receive approval of a trastuzumab in the United States, OGIVRI (Trastuzumab-dkst), as well as FULPHILA (Pegfilgrastim-jmdb) and the first U.S. approval of an interchangeable biosimilar for SEMGLEE (insulin glargine). Biocon Biologics has a comprehensive portfolio of in-market and in-development biosimilar products across multiple therapies, including seven approved biosimilars in the United States and six in Canada, with a development pipeline of 20 biosimilar assets, including insulins and monoclonal antibodies spanning multiple therapy areas.
Its parent company, Biocon Limited, publicly listed in 2004, is a global biopharmaceutical company. It has developed and commercialized novel biologics, biosimilars and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe.
Read also: Biocon Biologics receives EMA Committee positive opinions for Biosimilar Denosumab for bone health
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.